NYSE:LLYPharmaceuticals
Will FDA Breakthrough Status for KRAS Therapy Reshape Eli Lilly’s (LLY) Oncology Growth Story?
In the past week, Eli Lilly announced that the FDA granted Breakthrough Therapy designation to olomorasib in combination with pembrolizumab for first-line treatment of advanced or metastatic KRAS G12C-mutant non-small cell lung cancer, based on encouraging early and late-stage trial results.
This milestone accelerates the path to potential approval for a next-generation targeted lung cancer therapy and underscores Lilly's increasing presence in oncology innovation.
We'll explore how this FDA...